Table 1.
Baseline characteristics of CRIC Study participants with available biomarker data
| Characteristic | Adults with CKD, n=2466 |
|---|---|
| Age, yr, mean±SD | 59.5±10.8 |
| Women, N (%) | 1131 (46) |
| Race/ethnicity, N (%) | |
| Non-Hispanic white | 1049 (43) |
| Non-Hispanic black | 949 (38) |
| Hispanic | 378 (15) |
| Other | 90 (4) |
| Diabetes mellitus, N (%) | 1226 (50) |
| Cardiovascular disease, N (%) | 849 (34) |
| Urinary albumin-to-creatinine, mg/g, median (IQR) | 53 (6–503) |
| eGFR, ml/min per 1.73 m2, mean±SD | 44±18 |
| Systolic BP, mmHg, mean±SD | 127.1±22.1 |
| Diastolic BP, mmHg, mean±SD | 69.7±12.7 |
| Body mass index, kg/m2, mean±SD | 32.1±7.7 |
| ACEi/ARB | 69.6% |
| Aldosterone antagonist | 3.8% |
| Statins | 58.4% |
| Antiplatelet agents | 47.4% |
| KIM-1/Cr, ng/g, median (IQR) | 1399 (758–2618) |
| NGAL/Cr, mcg/g, median (IQR) | 12.75 (3.89–46.19) |
| L-FABP/Cr, mcg/g, median (IQR) | 7.31 (1.88–28.11) |
| NAG/Cr, U/g, median (IQR) | 4.03 (2.41–7.29) |
CRIC, Chronic Renal Insufficiency Cohort; IQR, interquartile range; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; KIM-1, kidney injury molecule-1; Cr, urinary creatinine; NGAL, neutrophil gelatinase-associated lipocalin; L-FABP, liver fatty acid-binding protein; NAG, N-acetyl-β-d-glucosaminidase.